Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lysanne A Lievense

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
American Journal of Respiratory and Critical Care Medicine|March 3, 2017
Checkpoint Blockade in Lung Cancer and MesotheliomaLysanne A Lievense, Daniel H Sterman, Robin Cornelissen, et al.
Translational Lung Cancer Research|March 26, 2015
Immunotherapy prospects in the treatment of lung cancer and mesotheliomaJoachim G Aerts, Lysanne A Lievense, Henk C Hoogsteden, et al.
JTO Clinical and Research Reports|December 29, 2022
Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse EffectsLysanne A Lievense, Peter Heukels, Nico C van Walree, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisFloris Dammeijer, Lysanne A Lievense, G D Marijn Veerman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2016
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell SuppressionLysanne A Lievense, Robin Cornelissen, Koen Bezemer, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2016
Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patientsLysanne A Lievense, Koen Bezemer, Robin Cornelissen, et al.
Plos One|September 6, 2014
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Alexander P Maat, et al.
Immunotherapy|November 15, 2012
Dendritic cell-based immunotherapy in mesotheliomaRobin Cornelissen, Lysanne A Lievense, Marlies E Heuvers, et al.
Lung Cancer (Amsterdam, Netherlands)|April 7, 2015
Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Jan-Lukas Robertus, et al.
Cancer Immunology Research|May 25, 2017
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC ImmunotherapyFloris Dammeijer, Lysanne A Lievense, Margaretha E Kaijen-Lambers, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
American Journal of Respiratory and Critical Care Medicine|March 3, 2017
Checkpoint Blockade in Lung Cancer and MesotheliomaLysanne A Lievense, Daniel H Sterman, Robin Cornelissen, et al.
Translational Lung Cancer Research|March 26, 2015
Immunotherapy prospects in the treatment of lung cancer and mesotheliomaJoachim G Aerts, Lysanne A Lievense, Henk C Hoogsteden, et al.
JTO Clinical and Research Reports|December 29, 2022
Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse EffectsLysanne A Lievense, Peter Heukels, Nico C van Walree, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisFloris Dammeijer, Lysanne A Lievense, G D Marijn Veerman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 16, 2016
Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell SuppressionLysanne A Lievense, Robin Cornelissen, Koen Bezemer, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2016
Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patientsLysanne A Lievense, Koen Bezemer, Robin Cornelissen, et al.
Plos One|September 6, 2014
Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Alexander P Maat, et al.
Immunotherapy|November 15, 2012
Dendritic cell-based immunotherapy in mesotheliomaRobin Cornelissen, Lysanne A Lievense, Marlies E Heuvers, et al.
Lung Cancer (Amsterdam, Netherlands)|April 7, 2015
Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesotheliomaRobin Cornelissen, Lysanne A Lievense, Jan-Lukas Robertus, et al.
Cancer Immunology Research|May 25, 2017
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC ImmunotherapyFloris Dammeijer, Lysanne A Lievense, Margaretha E Kaijen-Lambers, et al.
Pageof 2